Resveratrol-salicylate derivatives as selective DNMT3 inhibitors and anticancer agents

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 31, Issue 5, 2016, Pages 695-703

  Aldawsari, Fahad S ^a   Aguayo Ortiz, Rodrigo ^b   Kapilashrami, Kanishk ^c   Yoo, Jakyung ^d   Luo, Minkui ^c   Medina Franco, José L ^b   Velázquez Martínez, Carlos A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Universidad Nacional Autonoma de Mexico Facultad de Quimica   (Mexico)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d Daewoong Pharmaceutical Co Ltd   (South Korea)

Author keywords

Aspirin; chemoprevention; DNMT; docking; resveratrol

Indexed keywords

3,4,5 TRANS TRIMETHOXYSTILBENE; ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DNA METHYLTRANSFERASE INHIBITOR; RESVERATROL; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; DNA (CYTOSINE 5) METHYLTRANSFERASE; PROTEIN BINDING; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME INHIBITION ASSAY; HEPG2 CELL LINE; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MOLECULAR DOCKING; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVATION; HEP-G2 CELL LINE; HT-29 CELL LINE; IC50; METABOLISM; MOLECULAR MODEL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ENZYME ACTIVATION; HEP G2 CELLS; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; SALICYLATES; STILBENES;

EID: 84976494055     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2015.1058256     Document Type: Article

References (64)

1. S.Fulda. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today 2010;15:757–65
2. M.Athar, J.H.Back, L.Kopelovich,. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 2009;486:95–102
3. M.Athar, J.H.Back, X.Tang,. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007;224:274–83
4. S.K.Goswami, D.K.Das. Resveratrol and chemoprevention. Cancer Lett 2009;284:1–6
5. J.K.Kundu, Y.-J.Surh. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 2008;269:243–61
6. J.A.Baur, D.A.Sinclair. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5:493–506
7. P.Signorelli, R.Ghidoni. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 2005;16:449–66
8. M.Sengottuvelan, R.Senthilkumar, N.Nalini. Modulatory influence of dietary resveratrol during different phases of 1,2-dimethylhydrazine induced mucosal lipid-peroxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis. BBA Gen Subjects 2006;1760:1175–83
9. S.Das, D.K.Das. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2007;2:133–8
10. B.D.Gehm, A.S.Levenson, H.Liu,. Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF-1 and AF-2. J Steroid Biochem Mol Biol 2004;88:223–34
11. M.E.Juan, I.Alfaras, J.M.Planas. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res 2012;65:584–91
12. H.Gwak, G.Haegeman, B.K.Tsang, Y.S.Song. Cancer-specific interruption of glucose metabolism by resveratrol is mediated through inhibition of Akt/GLUT1 axis in ovarian cancer cells. Mol Carcinog 2014. [Epub ahead of print]. doi:10.1002/mc.22133
13. M.V.Clement, J.L.Hirpara, S.H.Chawdhury, S.Pervaiz. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998;92:996–1002
14. I.Tinhofer, D.Bernhard, M.Senfter,. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J 2001;15:1613–15
15. A.K.Joe, H.Liu, M.Suzui,. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 2002;8:893–903
16. Y.Bai, Q.-Q.Mao, J.Qin,. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 2010;101:488–93
17. H.T.Yin, Q.Z.Tian, L.Guan,. In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev 2013;14:1703–6
18. J.L.Medina-Franco, M.A.Giulianotti, G.S.Welmaker, R.A.Houghten. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today 2013;18:495–501
19. K.Pallauf, K.Giller, P.Huebbe, G.Rimbach. Nutrition and healthy ageing: calorie restriction or polyphenol-rich “MediterrAsian” diet? Oxid Med Cell Longev 2013;2013:707421
20. H.Denis, M.N.Ndlovu, F.Fuks. Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep 2011;12:647–56
21. A.Gnyszka, Z.Jastrzebski, S.Flis. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res 2013;33:2989–96
22. J.Gao, L.Wang, J.Xu,. Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. J Exp Clin Cancer Res 2013;32:86
23. W.Zhu, W.Qin, K.Zhang,. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr Cancer 2012;64:393–400
24. E.Capobianco, A.Mora, D.La Sala,. Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PLoS One 2014;9:e95596
25. S.Flis, A.Gnyszka, K.Flis. DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells. PLoS One 2014;9:e92305
26. R.Sandhu, A.G.Rivenbark, W.B.Coleman. Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b. Breast Cancer Res Treat 2012;131:385–99
27. H.J.Kim, J.H.Kim, E.K.Chie,. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol 2012;7:39
28. C.Chen, D.Pan, A.M.Deng,. DNA methyltransferases 1 and 3B are required for hepatitis C virus infection in cell culture. Virology 2013;441:57–65
29. P.Sin-Chan, A.Huang. DNMTs as potential therapeutic targets in high-risk pediatric embryonal brain tumors. Expert Opin Ther Targets 2014;18:1103–7
30. D.Subramaniam, R.Thombre, A.Dhar, S.Anant. DNA methyltransferases: a novel target for prevention and therapy. Front Oncol 2014;4:80
31. A.Erdmann, L.Halby, J.Fahy, P.B.Arimondo. Targeting DNA methylation with small molecules: what's next? J Med Chem 2014;58:2569--83
32. J.L.Medina-Franco, O.Méndez-Lucio, J.Yoo, A.Dueñas. Discovery and development of DNA methyltransferase inhibitors using in silico approaches. Drug Discov Today 2015;20:569--77
33. J.Fahy, A.Jeltsch, P.B.Arimondo. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin Ther Pat 2012;22:1427–42
34. B.Brueckner, R.G.Boy, P.Siedlecki,. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 2005;65:6305–11
35. M.Z.Fang, Y.M.Wang, N.Ai,. Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003;63:7563–70
36. O.Mendez-Lucio, J.Tran, J.L.Medina-Franco,. Toward drug repurposing in epigenetics: olsalazine as a hypomethylating compound active in a cellular context. Chem Med Chem 2014;9:560–5
37. D.Kuck, N.Singh, F.Lyko, J.L.Medina-Franco. Novel and selective DNA methyltransferase inhibitors: docking-based virtual screening and experimental evaluation. Bioorg Med Chem 2010;18:822–9
38. F.S.Aldawsari, O.H.Elshenawy, M.A.El Gendy,. Design and synthesis of resveratrol-salicylate hybrid derivatives as CYP1A1 inhibitors. J Enzyme Inhib Med Chem 2014. [Epub ahead of print]. doi: 10.3109/14756366.2014.979347
39. W.Qin, K.Zhang, K.Clarke,. Methylation and miRNA effects of resveratrol on mammary tumors vs. normal tissue. Nutr Cancer 2014;66:270–7
40. I.Hemeon, J.A.Gutierrez, M.-C.Ho, V.L.Schramm. Characterizing DNA methyltransferases with an ultrasensitive luciferase-linked continuous assay. Anal Chem 2011;83:4996–5004
41. J.Song, O.Rechkoblit, T.H.Bestor, D.J.Patel. Structure of DNMT1–DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science 2011;331:1036–40
42. W.Zheng, G.Ibáñez, H.Wu,. Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2. J Am Chem Soc 2012;134:18004–14
43. Macromdel, version 9.8., New York, NY: Schrödinger, LLC; 2010
44. E.F.Pettersen, T.D.Goddard, C.C.Huang,. UCSF Chimera – a visualization system for exploratory research and analysis. J Comput Chem 2004;25:1605–12
45. G.M.Morris, R.Huey, W.Lindstrom,. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 2009;30:2785–91
46. Y.Chen, F.Hu, Y.Gao,. Design, synthesis, and evaluation of methoxylated resveratrol derivatives as potential antitumor agents. Res Chem Intermed 2013;41:2725–38
47. T.Mikeska, J.M.Craig. DNA methylation biomarkers: cancer and beyond. Genes (Basel) 2014;5:821–64
48. R.Cacabelos, C.Torrellas. Epigenetic drug discovery for Alzheimer's disease. Expert Opin Drug Discov 2014;9:1059–86
49. P.Chaturvedi, S.C.Tyagi. Epigenetic mechanisms underlying cardiac degeneration and regeneration. Int J Cardiol 2014;173:1–11
50. K.Stankov, D.Benc, D.Draskovic. Genetic and epigenetic factors in etiology of diabetes mellitus type 1. Pediatrics 2013;132:1112–22
51. S.A.Ross. Diet and DNA methylation interactions in cancer prevention. Ann NY Acad Sci 2003;983:197–207
52. J.L.Medina-Franco, J.Yoo. Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: insights to unveil inhibitors in chemical databases. Mol Divers 2013;17:337–44
53. J.Yoo, S.Choi, J.L.Medina-Franco. Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs. PLoS One 2013;8:e62152
54. L.Isakovic, O.M.Saavedra, D.B.Llewellyn,. Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett 2009;19:2742–6
55. O.M.Saavedra, L.Isakovic, D.B.Llewellyn,. SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes. Bioorg Med Chem Lett 2009;19:2747–51
56. J.L.Medina-Franco, O.Mendez-Lucio, J.Yoo. Rationalization of activity cliffs of a sulfonamide inhibitor of DNA methyltransferases with induced-fit docking. Int J Mol Sci 2014;15:3253–61
57. J.A.Kilgore, X.L.Du, L.Melito,. Identification of DNMT1 selective antagonists using a novel scintillation proximity assay. J Biol Chem 2013;288:19673–84
58. E.Rilova, A.Erdmann, C.Gros,. Design, synthesis and biological evaluation of 4-amino-N-(4-aminophenyl)benzamide analogues of quinoline-based SGI-1027 as inhibitors of DNA methylation. Chem Med Chem 2014;9:590–601
59. T.Suzuki, R.Tanaka, S.Hamada,. Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. Bioorg Med Chem Lett 2010;20:1124–7
60. S.Asgatay, C.Champion, G.Marloie,. Synthesis and evaluation of analogues of N-phthaloyl-l-tryptophan (RG108) as inhibitors of DNA methyltransferase 1. J Med Chem 2013;57:421–34
61. M.Bello, M.Martinez-Archundia, J.Correa-Basurto. Automated docking for novel drug discovery. Expert Opin Drug Discov 2013;8:821–34
62. D.Kuck, T.Caulfield, F.Lyko, J.L.Medina-Franco. Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther 2010;9:3015–23
63. Q.Sun, Y.Xie, G.Wang, J.Li. Identification of genes in HepG2 cells that respond to DNA methylation and histone deacetylation inhibitor treatment. Exp Ther Med 2014;8:813–17
64. F.F.Costa, N.V.Verbisck, A.C.Salim,. Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene 2004;23:1481–8